Avalo Therapeutics: director Rita Jain received 1,322 shares

What happened The filing reports that Rita Jain, a director of Avalo Therapeutics, received 1,322 shares via an option grant (derivative) on Sep 30, 2026, with an exercise price of $12.29 per share, for a total reported value of $16,247. The filing shows the options were granted and are 100% vested.

Key details

• Transaction date and price: Sep 30, 2026; $12.29 per share.
• Shares involved: 1,322 shares (derivative/options).
• Shares owned after the transaction: not reported in the filing.
• Footnotes: the options were granted on Sep 30, 2026 and are 100% vested (F1); the options were issued under the issuer’s amended and restated non-employee director compensation plan in lieu of board fees (F2).
• Form filed on Oct 2, 2026; the filing does not indicate a late report.

Why it may matter

• This was an award/grant of options (derivative), not a market sale or purchase, and the filing does not report an exercise or disposition of the shares.
• The filing does not show why the insider traded or why the company acted.